BioNTech SE (NASDAQ:BNTX - Get Free Report) shares gapped down prior to trading on Friday . The stock had previously closed at $100.25, but opened at $96.49. BioNTech shares last traded at $94.43, with a volume of 201,480 shares trading hands.
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on BNTX shares. Citigroup restated a "buy" rating and issued a $140.00 target price (down previously from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. The Goldman Sachs Group began coverage on BioNTech in a research report on Thursday, May 29th. They issued a "neutral" rating and a $110.00 price objective on the stock. JPMorgan Chase & Co. reduced their target price on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a research report on Thursday, May 22nd. HC Wainwright restated a "buy" rating and issued a $134.00 price objective on shares of BioNTech in a report on Thursday, May 22nd. Finally, Truist Financial restated a "buy" rating and issued a $155.00 price target (up previously from $151.00) on shares of BioNTech in a report on Tuesday. One analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, BioNTech has an average rating of "Moderate Buy" and a consensus price target of $139.14.
Check Out Our Latest Report on BioNTech
BioNTech Stock Up 3.5%
The company's fifty day simple moving average is $97.78 and its 200-day simple moving average is $108.21. The firm has a market capitalization of $28.14 billion, a PE ratio of -55.74 and a beta of 1.35. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21.
BioNTech (NASDAQ:BNTX - Get Free Report) last announced its earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.24 billion. During the same period in the previous year, the business earned $1.90 EPS. The firm's revenue for the quarter was down 19.5% on a year-over-year basis. On average, analysts forecast that BioNTech SE will post -3.88 EPS for the current year.
Hedge Funds Weigh In On BioNTech
Hedge funds have recently modified their holdings of the stock. Banque Cantonale Vaudoise purchased a new stake in BioNTech during the 1st quarter worth approximately $36,000. Jones Financial Companies Lllp raised its holdings in shares of BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock worth $53,000 after buying an additional 246 shares during the last quarter. Quintet Private Bank Europe S.A. lifted its stake in shares of BioNTech by 823.5% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock worth $88,000 after buying an additional 700 shares during the period. Allianz SE purchased a new stake in shares of BioNTech during the fourth quarter valued at $90,000. Finally, Banque Transatlantique SA acquired a new position in shares of BioNTech in the 1st quarter valued at $80,000. Institutional investors and hedge funds own 15.52% of the company's stock.
BioNTech Company Profile
(
Get Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Featured Articles
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
